98%
921
2 minutes
20
Background And Aims: The ankle-brachial index (ABI) is a diagnostic test for screening and detecting peripheral artery disease (PAD), as well as a risk enhancer in the AHA/ACC guidelines on the primary prevention of atherosclerotic cardiovascular disease (ASCVD). However, our understanding of the association between ABI and cardiovascular risk in contemporary older populations is limited. Additionally, the prognostic value of ABI among individuals with prior ASCVD is not well understood.
Methods: Among 5,003 older adults at ARIC visit 5 (2011-2013) (4,160 without prior ASCVD [median age 74 years, 38% male], and 843 with ASCVD [median age 76 years, 65% male]), we quantified the association between ABI and the risk of heart failure (HF), and composite coronary heart disease and stroke (CHD/stroke) using multivariable Cox regression models.
Results: Over a median follow-up of 5.5 years, we observed 400 CHD/stroke events and 338 HF cases (242 and 199 cases in those without prior ASCVD, respectively). In participants without a history of ASCVD, a low ABI ≤0.9 (relative to ABI 1.11-1.20) was associated with both CHD/stroke and HF (adjusted hazard ratios 2.40 [95% CI: 1.55-3.71] and 2.23 [1.40-3.56], respectively). In those with prior ASCVD, low ABI was not significantly associated with CHD/stroke, but was with HF (7.12 [2.47-20.50]). The ABI categories of 0.9-1.2 and > 1.3 were also independently associated with increased HF risk. Beyond traditional risk factors, ABI significantly improved the risk discrimination of CHD/stroke in those without ASCVD and HF, regardless of baseline ASCVD.
Conclusions: Low ABI was associated with CHD/stroke in those without prior ASCVD and higher risk of HF regardless of baseline ASCVD status. These results support ABI as a risk enhancer for guiding primary cardiovascular prevention and suggest its potential value in HF risk assessment for older adults.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604439 | PMC |
http://dx.doi.org/10.1016/j.atherosclerosis.2021.09.028 | DOI Listing |
BMJ Open
September 2025
Centro de Investigaciones Clínicas, Fundación Valle del Lili Cali, Cali, Valle del Cauca, Colombia
Introduction: Elevated lipid profiles increase the risk of atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality worldwide. Despite the availability of lipid-lowering therapy (LLT), adherence to therapy and achievement of Low-Density Lipoprotein Cholesterol (LDL-C) target levels remain suboptimal. Coronary artery disease (CAD) presents substantial public health challenges, with LDL-C goal attainment rates reported to be between 30.
View Article and Find Full Text PDFAm J Prev Cardiol
September 2025
Department of Medicine, University of Pittsburgh School of Medicine, USA.
Objective: The value of lipid lowering therapy (LLT) for prevention of atherosclerotic cardiovascular disease (ASCVD) is well understood. American College of Cardiology and American Heart Association guidelines recommend statin therapy for secondary and high-risk primary ASCVD prevention. Prior studies have identified incomplete uptake of these guidelines in specific practice settings or patient populations.
View Article and Find Full Text PDFEur J Prev Cardiol
September 2025
Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037.
Background: When Apolipoprotein B (ApoB) is discordant with either LDL cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C), ApoB is a stronger predictor of atherosclerotic cardiovascular disease (ASCVD). It is unclear whether ApoB also provides better risk stratification when ApoB and LDL particle number (LDL-P) are discordant.
Purpose: Here we examine the relationship between ApoB and LDL-P in the UK Biobank to determine which biomarker provides more accurate risk prediction when ApoB and LDL-P are discordant.
Maturitas
August 2025
Department of Epidemiology and Public Health, Foch Hospital, Suresnes, 92150, France. Electronic address:
Background: Menopause induces hormonal and metabolic changes that may increase the risk of atherosclerotic cardiovascular disease (ASCVD). However, the contribution of menopause to ASCVD risk, beyond aging, remains debated. This study investigated the association between menopause and ASCVD risk in a large population-based cohort.
View Article and Find Full Text PDFClin Res Cardiol
August 2025
Center for Health Services Research of the German Cardiac Society (DGK-ZfKVF), German Cardiac Society, Duesseldorf, Germany.
Aims: Office-based cardiologists (OBCs) and general practitioners (GPs) follow different approaches for hypercholesterolemia management in atherosclerotic cardiovascular disease (ASCVD). This study evaluates whether differences in clinical practice between OBCs and GPs contribute to existing gaps in low-density lipoprotein cholesterol (LDL-C) control and lipoprotein(a) [Lp(a)] screening in ASCVD care.
Methods: LipidSnapshot is a collaborative research initiative comprising a prospective non-interventional study at OBCs and a retrospective analysis of GP records.